Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12561568 | 0.86 | CA2 (0.52) | PPARATSHRTNNC1S1PR1SGPL1 | |
| SCHEMBL12561705 | 0.85 | TNNC1 (0.43) | PPARGPPARACHKATNNC1S1PR1 | |
| SCHEMBL2600042 | 0.81 | ESR1 (0.60) | ESR1CA2 | |
| SCHEMBL12561897 | 0.79 | DAO (0.42) | TSHRS1PR1NOS3NOS1PRSS1 | |
| SCHEMBL21076151 | 0.78 | CYP1A2 (0.52) | CHKATSHR | |
| SCHEMBL31277355 | 0.78 | TAAR1 (0.52) | TSHRTNNC1S1PR1SGPL1S1PR4 | |
| SCHEMBL13183177 | 0.77 | PPARG (0.36) | PPARGPPARACHKATSHRTNNC1 | |
| SCHEMBL23095140 | 0.76 | ESR1 (0.33) | TNNC1S1PR1SGPL1S1PR4GPR183 | |
| SCHEMBL7388083 | 0.76 | GFER (0.59) | TSHRESR1 | |
| SCHEMBL21507869 | 0.76 | ESR1 (0.33) | TNNC1S1PR1SGPL1S1PR4GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714213-B2 | 4-aminomethylbenzoic acid derivative | TOA EIYO LTD. (JP) | 2017-07-25 | — | — | US | disclosed |
| US-9714213-B2 | 4-aminomethylbenzoic acid derivative | TOA EIYO LTD. (JP) | 2017-07-25 | — | — | US | disclosed |
| US-9586914-B2 | Modulators of C3a receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-03-07 | — | — | US | disclosed |
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-09-22 | — | — | US | disclosed |
| US-20160264514-A1 | 4-AMINOMETHYLBENZOIC ACID DERIVATIVE | TOA EIYO LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20160264514-A1 | 4-AMINOMETHYLBENZOIC ACID DERIVATIVE | TOA EIYO LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3059224-A1 | 4-AMINOMETHYLBENZOIC ACID DERIVATIVE | TOA Eiyo Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-9328071-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2016-05-03 | — | — | US | disclosed |
| US-20140309264-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-10-16 | — | — | US | disclosed |
| US-20140302069-A1 | MODULATORS OF C3A RECEPTORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-10-09 | — | — | US | disclosed |
| US-8802720-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20130225605-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-08-29 | — | — | US | disclosed |
| US-8445530-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-01-31 | — | — | US | disclosed |
| US-8362073-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-8211935-B2 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110178061-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264514-A1 | 4-AMINOMETHYLBENZOIC ACID DERIVATIVE | ALDH7A1, CYP2B6, CYP2A6 | PPARG 600/4885PPARA 860/4885CHKA 3571/4885 |
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | PPARG 589/4885PPARA 606/4885CHKA 2017/4885 |
| US-20130225605-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | PPARG 589/4885PPARA 606/4885CHKA 2017/4885 |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | PPARG 589/4885PPARA 606/4885CHKA 2017/4885 |
| US-20110178061-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | CACNA1D, ORAI1, CACNA1C | PPARG 3028/4885PPARA 3608/4885CHKA 933/4885 |
| US-20140302069-A1 | MODULATORS OF C3A RECEPTORS | C3AR1, C5AR2, C5AR1 | PPARG 1186/4885PPARA 1081/4885CHKA 1874/4885 |
| US-20140309264-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | PPARG 589/4885PPARA 606/4885CHKA 2017/4885 |
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | PPARG 589/4885PPARA 606/4885CHKA 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.